Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.01 USD
−98.82 M USD
0.00 USD
24.97 M
About Oculis Holding AG
Sector
CEO
Riad Sherif
Headquarters
Zug
Website
Founded
2016
ISIN
CH1242303498
FIGI
BBG01BJ1BHZ3
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OCS is 14.76 USD — it has increased by 0.07% in the past 24 hours. Watch Oculis Holding AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oculis Holding AG stocks are traded under the ticker OCS.
OCS stock has risen by 0.34% compared to the previous week, the month change is a −10.49% fall, over the last year Oculis Holding AG has showed a 50.54% increase.
We've gathered analysts' opinions on Oculis Holding AG future price: according to them, OCS price has a max estimate of 36.40 USD and a min estimate of 19.94 USD. Watch OCS chart and read a more detailed Oculis Holding AG stock forecast: see what analysts think of Oculis Holding AG and suggest that you do with its stocks.
OCS stock is 1.30% volatile and has beta coefficient of −0.39. Track Oculis Holding AG stock price on the chart and check out the list of the most volatile stocks — is Oculis Holding AG there?
Today Oculis Holding AG has the market capitalization of 616.16 M, it has increased by 4.31% over the last week.
Yes, you can track Oculis Holding AG financials in yearly and quarterly reports right on TradingView.
Oculis Holding AG is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
OCS earnings for the last quarter are −0.57 USD per share, whereas the estimation was −0.56 USD resulting in a −1.94% surprise. The estimated earnings for the next quarter are −0.49 USD per share. See more details about Oculis Holding AG earnings.
Oculis Holding AG revenue for the last quarter amounts to 236.01 K USD, despite the estimated figure of 288.19 K USD. In the next quarter, revenue is expected to reach 270.88 K USD.
OCS net income for the last quarter is −23.30 M USD, while the quarter before that showed −23.04 M USD of net income which accounts for −1.14% change. Track more Oculis Holding AG financial stats to get the full picture.
No, OCS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 36.00 employees. See our rating of the largest employees — is Oculis Holding AG on this list?
Like other stocks, OCS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oculis Holding AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oculis Holding AG technincal analysis shows the neutral today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oculis Holding AG stock shows the buy signal. See more of Oculis Holding AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.